Trials / Recruiting
RecruitingNCT07063030
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
An Exploratory Clinical Study to Evaluate LX107 Gene Therapy in Patients With AIPL1 Biallelic Mutation-related Inherited Retinal Dystrophy (AIPL1-IRD)
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 13 (estimated)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | LX107 Injection | Subjects will receive subretinal injection of LX107 on Day 0. |
Timeline
- Start date
- 2025-07-15
- Primary completion
- 2026-12-31
- Completion
- 2030-12-31
- First posted
- 2025-07-14
- Last updated
- 2026-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07063030. Inclusion in this directory is not an endorsement.